arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Scholar Rock Holding Corporation

SRRK Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$41.96
▲ +1.4% Today
as of Oct 22, 16:52 ET
Last 30 days -19.07% Sep 14 → Oct 22
$38.62 $42.17 $45.72 $49.28 $52.83 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$42.54
High
$43.35
Low
$41.50
Volume
$1M
Avg Vol
$2M
Mkt Cap
$5.6B
P/E (TTM)
—
Beta
—
52w High
$61.76
52w Low
$27.07
Div Yield
—
Shares Out
$122M

Recent Press Releases & News last 60 days · 25 items

Oct 20 · 12:00 PR Business Wire
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
Oct 16 · 20:15 PR Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 16 · 01:20 Simply Wall St.
EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK)
▸ Show all 25 press releases & news Free account →

SRRK earnings at a glance

The options market is pricing a move of about ±7.6% after the report, a range of roughly $38.77 to $45.15 from today's $41.96. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±2.1% on average; after the most recent report on May 7, 2026 it moved -1.4%. That means options currently expect more movement than SRRK has typically delivered. SRRK beat the consensus EPS estimate in 0 of its last 4 reported quarters. Implied volatility is currently 64%. The share price of $41.96 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$27
$62
43% of range
Avg surprise (last 4)
-14.6%
Avg reaction (last 2)
-2.1%
0% positive
Latest IV / EM
64%
EM ±7.6% · $45 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.98$-0.85$-0.72$-0.60$-0.47 Actual $-0.49Actual $-0.47Actual $-0.53Actual $-0.59Actual $-0.60Actual $-0.66Actual $-0.67Est $-0.63Actual $-0.98Est $-0.66Actual $-0.90Est $-0.88Actual $-0.83Est $-0.82Actual $-0.84 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-110M$-99M$-89M$-78M$-68M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.84 — — — — financials
Thu May 7, 2026Mar/2026 $-0.83 $-0.82 -1.2% -23.9% -1.4% earnings
Fri Nov 14, 2025Sep/2025 $-0.90 $-0.88 -2.3% — — earnings
Wed Aug 6, 2025Jun/2025 $-0.98 $-0.66 -48.5% — — earnings
Wed May 14, 2025Mar/2025 $-0.67 $-0.63 -6.3% — -2.7% earnings
Mon Sep 30, 2024Sep 2024 $-0.66 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.60 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.59 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.53 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.47 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.49 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue—$0——————
Cost of revenue————————
Gross profit————————
Operating income$-109M$-102M—$-104M$-112M$-77M—$-65M
Net income$-110M$-106M—$-102M$-110M$-75M—$-64M
EPS (diluted)$-0.84$-0.83—$-0.90$-0.98$-0.67—$-0.66

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$437M$431M$324M$287M$153M$138M$178M$76M
Inventory————————
Total current assets$507M$515M$385M$391M$319M$385M$451M$153M
Total assets$524M$535M$404M$412M$340M$408M$475M$179M
Long-term debt$196M$197M$100M$100M$50M$50M$50M$50M
Total liabilities$270M$259M$159M$167M$107M$95M$106M$100M
Total equity$254M$276M$245M$245M$233M$312M$369M$79M

Implied volatility — last 90 days

41%98%154%211%267% Jun 08 — IV 76% · EM ±10.1%Jun 09 — IV 61% · EM ±7.6%Jun 10 — IV 81% · EM ±9.5%Jun 11 — IV 78% · EM ±8.6%Jun 12 — IV 61% · EM ±6.2%Jun 15 — IV 75% · EM ±5.4%Jun 16 — IV 102% · EM ±6.0%Jun 17 — IV 268% · EM ±11.2%Jun 19 — IV 57% · EM ±12.6%Jun 22 — IV 56% · EM ±11.7%Jun 23 — IV 63% · EM ±12.8%Jun 24 — IV 62% · EM ±12.3%Jun 25 — IV 59% · EM ±11.5%Jun 26 — IV 53% · EM ±10.1%Jun 29 — IV 60% · EM ±10.6%Jun 30 — IV 61% · EM ±10.5%Jul 01 — IV 56% · EM ±9.4%Jul 02 — IV 52% · EM ±8.4%Jul 03 — IV 54% · EM ±8.4%Jul 06 — IV 62% · EM ±8.6%Jul 07 — IV 63% · EM ±8.4%Jul 08 — IV 60% · EM ±7.5%Jul 09 — IV 71% · EM ±8.4%Jul 10 — IV 60% · EM ±6.6%Jul 13 — IV 81% · EM ±6.8%Jul 14 — IV 103% · EM ±7.5%Jul 15 — IV 110% · EM ±6.5%Jul 16 — IV 197% · EM ±8.2%Jul 20 — IV 63% · EM ±15.0%Jul 21 — IV 63% · EM ±14.6%Jul 22 — IV 67% · EM ±15.4%Jul 23 — IV 68% · EM ±15.2%Jul 24 — IV 63% · EM ±13.9%Jul 27 — IV 60% · EM ±12.6%Jul 28 — IV 74% · EM ±15.1%Jul 29 — IV 74% · EM ±14.7%Jul 30 — IV 58% · EM ±11.4%Jul 31 — IV 68% · EM ±13.1%Aug 03 — IV 67% · EM ±11.8%Aug 04 — IV 84% · EM ±14.4%Aug 05 — IV 81% · EM ±13.5%Aug 06 — IV 56% · EM ±9.0%Aug 07 — IV 101% · EM ±15.8%Aug 10 — IV 62% · EM ±8.6%Aug 11 — IV 60% · EM ±8.0%Aug 12 — IV 80% · EM ±10.0%Aug 13 — IV 89% · EM ±10.5%Aug 14 — IV 67% · EM ±7.4%Aug 17 — IV 82% · EM ±6.9%Aug 18 — IV 80% · EM ±5.8%Aug 19 — IV 122% · EM ±7.2%Aug 20 — IV 115% · EM ±4.8%Aug 24 — IV 53% · EM ±11.0%Aug 25 — IV 63% · EM ±13.0%Aug 26 — IV 47% · EM ±9.5%Aug 27 — IV 53% · EM ±10.3%Aug 28 — IV 59% · EM ±11.3%Aug 31 — IV 47% · EM ±8.4%Sep 01 — IV 51% · EM ±8.8%Sep 02 — IV 60% · EM ±10.0%Sep 03 — IV 53% · EM ±8.6%Sep 04 — IV 42% · EM ±6.5%Sep 07 — IV 47% · EM ±6.5%Sep 08 — IV 62% · EM ±8.2%Sep 09 — IV 63% · EM ±7.9%Sep 10 — IV 76% · EM ±8.9%Sep 11 — IV 69% · EM ±7.6%Sep 14 — IV 92% · EM ±7.7%Sep 15 — IV 64% · EM ±4.7%Sep 16 — IV 58% · EM ±3.4%Sep 17 — IV 166% · EM ±6.9%Sep 21 — IV 58% · EM ±12.0%Sep 22 — IV 57% · EM ±11.6%Sep 23 — IV 53% · EM ±10.5%Sep 24 — IV 54% · EM ±10.5%Sep 25 — IV 52% · EM ±9.9%Sep 28 — IV 47% · EM ±8.3%Sep 29 — IV 58% · EM ±10.0%Sep 30 — IV 54% · EM ±9.1%Oct 01 — IV 52% · EM ±8.4%Oct 02 — IV 58% · EM ±9.0%Oct 05 — IV 94% · EM ±13.0%Oct 06 — IV 76% · EM ±10.0%Oct 07 — IV 86% · EM ±10.8%Oct 08 — IV 64% · EM ±7.6%

Sector peers

IOVA
Iovance Biotherapeutics, Inc.
$5.9B $14.14-4.8%
CRSP
CRISPR Therapeutics AG
$5.4B $49.99+0.2%
CGON
CG Oncology, Inc.
$6.1B $62.54+1.0%
KOD
Kodiak Sciences Inc
$6.2B $85.78-7.7%
IMVT
Immunovant, Inc.
$7.0B $29.10+1.8%
ADPT
Adaptive Biotechnologies Corporation
$4.2B $24.41-0.0%

SRRK earnings FAQ

What is SRRK's expected move for earnings?

Options currently price a move of about ±7.6%, or $3.19 per share either way from $41.96.

How does SRRK stock usually react to earnings?

Across the last 2 reports the average next-day move was ±2.1%, up 0 times and down 2 times.

What is SRRK's implied volatility?

SRRK's at-the-money implied volatility is about 64% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in